Glenmark Pharmaceuticals Limited
Glenmark Pharmaceuticals Limited, together with its subsidiaries, develops, manufactures, and sells generics, specialty medicines, and over the counter (OTC) pharmaceutical products in India, North America, Europe, and internationally. The company provides branded, OTC, and generic formulations in the therapeutic areas of dermatology, respiratory, oncology, immunology, pain management, hypertensi… Read more
Glenmark Pharmaceuticals Limited (GLENMARK) - Total Liabilities
Latest total liabilities as of September 2025: ₹94.20 Billion INR
Based on the latest financial reports, Glenmark Pharmaceuticals Limited (GLENMARK) has total liabilities worth ₹94.20 Billion INR as of September 2025.
Total liabilities represent everything the company owes to external parties, combining both current liabilities—like accounts payable, short-term debt, and accrued expenses—and non-current liabilities such as long-term debt, pension obligations, lease liabilities, and deferred tax liabilities.
Glenmark Pharmaceuticals Limited - Total Liabilities Trend (2004–2025)
This chart illustrates how Glenmark Pharmaceuticals Limited's total liabilities have evolved over time, based on quarterly financial data. Explore and compare other companies by total liabilities.
Glenmark Pharmaceuticals Limited Competitors by Total Liabilities
The table below lists competitors of Glenmark Pharmaceuticals Limited ranked by their total liabilities.
| Company | Country | Total Liabilities |
|---|---|---|
|
KION GROUP AG
OTCGREY:KNNGF
|
USA | $12.55 Billion |
|
Lagercrantz Group AB (publ)
ST:LAGR-B
|
Sweden | Skr8.52 Billion |
|
Nan Ya Printed Circuit Board Corp
TW:8046
|
Taiwan | NT$15.08 Billion |
|
Electric Power Development Co. Ltd
F:FJG
|
Germany | €2.21 Trillion |
|
nLIGHT Inc
NASDAQ:LASR
|
USA | $91.36 Million |
|
Maxscend Microelectronics Co Ltd
SHE:300782
|
China | CN¥4.71 Billion |
|
CommVault Systems Inc
NASDAQ:CVLT
|
USA | $1.82 Billion |
|
Bumrungrad Hospital PCL
BK:BH
|
Thailand | ฿4.64 Billion |
Liability Composition Analysis (2004–2025)
This chart breaks down Glenmark Pharmaceuticals Limited's total liabilities into key components over time: long-term debt, short-term debt, other current liabilities, and other non-current liabilities. Toggle between absolute values and percentage view to see how the composition has shifted.
Liquidity & Leverage Metrics
Key Metrics Explained
| Metric | Value | Description |
|---|---|---|
| Current Ratio | 1.65 | Measures ability to pay short-term obligations (Current Assets ÷ Current Liabilities) |
| Quick Ratio | N/A | More stringent measure of short-term liquidity ((Current Assets - Inventory) ÷ Current Liabilities) |
| Cash Ratio | N/A | Most conservative liquidity measure (Cash & Equivalents ÷ Current Liabilities) |
| Debt to Equity | 0.98 | Measures financial leverage (Total Liabilities ÷ Shareholder Equity) |
| Debt to Assets | 0.50 | Portion of assets financed with debt (Total Liabilities ÷ Total Assets) |
Liability Trends Comparison
This chart compares key liability metrics across different time periods, showing how Glenmark Pharmaceuticals Limited's debt structure has evolved. The comparison includes total liabilities, long-term debt, and current liabilities.
Annual Total Liabilities for Glenmark Pharmaceuticals Limited (2004–2025)
The table below shows the annual total liabilities of Glenmark Pharmaceuticals Limited from 2004 to 2025.
| Year | Total Liabilities | Change |
|---|---|---|
| 2025-03-31 | ₹72.00 Billion | +10.59% |
| 2024-03-31 | ₹65.11 Billion | -31.70% |
| 2023-03-31 | ₹95.32 Billion | +24.69% |
| 2022-03-31 | ₹76.45 Billion | -10.47% |
| 2021-03-31 | ₹85.39 Billion | -0.88% |
| 2020-03-31 | ₹86.15 Billion | +12.01% |
| 2019-03-31 | ₹76.91 Billion | +3.48% |
| 2018-03-31 | ₹74.32 Billion | +2.19% |
| 2017-03-31 | ₹72.73 Billion | +10.77% |
| 2016-03-31 | ₹65.66 Billion | -1.81% |
| 2015-03-31 | ₹66.87 Billion | +18.63% |
| 2014-03-31 | ₹56.37 Billion | +28.59% |
| 2013-03-31 | ₹43.84 Billion | +26.81% |
| 2012-03-31 | ₹34.57 Billion | +13.94% |
| 2011-03-31 | ₹30.34 Billion | +20.61% |
| 2010-03-31 | ₹25.16 Billion | -5.29% |
| 2009-03-31 | ₹26.56 Billion | +86.24% |
| 2008-03-31 | ₹14.26 Billion | +13.42% |
| 2007-03-31 | ₹12.57 Billion | +31.24% |
| 2006-03-31 | ₹9.58 Billion | +62.86% |
| 2005-03-31 | ₹5.88 Billion | +166.28% |
| 2004-03-31 | ₹2.21 Billion | -- |